Rong Liu1,2,3,4, Ya-Zhou Liao5, Wei Zhang1,2,3,4, Hong-Hao Zhou1,2,3,4. 1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China. 2. Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China. 3. Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China. 4. National Clinical Research Center for Geriatric Disorders, Changsha, China. 5. Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China.
Abstract
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with high heterogeneity and dismal survival rates. Tumor immune microenvironment plays a critical role in sensitive to chemotherapy and prognosis. Herein, we determined the relevance of the composition of tumor-infiltrating immune cells to clinical outcomes in PDACs, and we evaluated these effects by molecular subtype. EXPERIMENTAL DESIGN: Data of 1,274 samples from publically available datasets were collected. Molecular subtypes were predicted with support vector machine. Twenty-two subsets of immune cells were estimated with CIBERSORTx. The associations between each cell subset and overall survival (OS), relapse free survival (RFS), and complete response (CR) to chemotherapy were evaluated, modelling cellular proportions as quartiles. RESULTS: An immune-related cluster was identified with unsupervised hierarchical clustering of hallmark pathways. Of the immune cells investigated, M0 macrophages emerged as closely associated with worse OS (HR =1.23, 95% CI = 1.15-1.31, p=1.57×10-9) and RFS (HR = 1.14, 95% CI =1.04-1.25, p=2.93×10-3), regardless of molecular subtypes. The CD8+ T cells conferred favorable survival. The neutrophils conferred poor OS overall (HR=1.17, 95% CI=1.10-1.23, p=1.74×10-7) and within the classical subtype. In the basal-like subtype, activated mast cells were associated with worse OS. Consensus clustering revealed six immune subgroups with distinct survival patterns and CR rates. The higher expression of PD1 was associated with better OS. CONCLUSIONS: The immune cellular composition infiltrate in PDAC are likely to have effects on prognosis. Further exploration of the cellular immune response has the potential to identify candidates for immunotherapy.
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with high heterogeneity and dismal survival rates. Tumor immune microenvironment plays a critical role in sensitive to chemotherapy and prognosis. Herein, we determined the relevance of the composition of tumor-infiltrating immune cells to clinical outcomes in PDACs, and we evaluated these effects by molecular subtype. EXPERIMENTAL DESIGN: Data of 1,274 samples from publically available datasets were collected. Molecular subtypes were predicted with support vector machine. Twenty-two subsets of immune cells were estimated with CIBERSORTx. The associations between each cell subset and overall survival (OS), relapse free survival (RFS), and complete response (CR) to chemotherapy were evaluated, modelling cellular proportions as quartiles. RESULTS: An immune-related cluster was identified with unsupervised hierarchical clustering of hallmark pathways. Of the immune cells investigated, M0 macrophages emerged as closely associated with worse OS (HR =1.23, 95% CI = 1.15-1.31, p=1.57×10-9) and RFS (HR = 1.14, 95% CI =1.04-1.25, p=2.93×10-3), regardless of molecular subtypes. The CD8+ T cells conferred favorable survival. The neutrophils conferred poor OS overall (HR=1.17, 95% CI=1.10-1.23, p=1.74×10-7) and within the classical subtype. In the basal-like subtype, activated mast cells were associated with worse OS. Consensus clustering revealed six immune subgroups with distinct survival patterns and CR rates. The higher expression of PD1 was associated with better OS. CONCLUSIONS: The immune cellular composition infiltrate in PDAC are likely to have effects on prognosis. Further exploration of the cellular immune response has the potential to identify candidates for immunotherapy.
Authors: Richard E Royal; Catherine Levy; Keli Turner; Aarti Mathur; Marybeth Hughes; Udai S Kammula; Richard M Sherry; Suzanne L Topalian; James C Yang; Israel Lowy; Steven A Rosenberg Journal: J Immunother Date: 2010-10 Impact factor: 4.456
Authors: Andrew J Gentles; Aaron M Newman; Chih Long Liu; Scott V Bratman; Weiguo Feng; Dongkyoon Kim; Viswam S Nair; Yue Xu; Amanda Khuong; Chuong D Hoang; Maximilian Diehn; Robert B West; Sylvia K Plevritis; Ash A Alizadeh Journal: Nat Med Date: 2015-07-20 Impact factor: 53.440
Authors: Miriam Lohr; Karolina Edlund; Johan Botling; Seddik Hammad; Birte Hellwig; Amnah Othman; Anders Berglund; Mats Lambe; Lars Holmberg; Simon Ekman; Michael Bergqvist; Fredrik Pontén; Cristina Cadenas; Rosemarie Marchan; Jan G Hengstler; Jörg Rahnenführer; Patrick Micke Journal: Cancer Lett Date: 2013-01-28 Impact factor: 8.679
Authors: Adile Orhan; Rasmus P Vogelsang; Malene B Andersen; Michael T Madsen; Emma R Hölmich; Hans Raskov; Ismail Gögenur Journal: Eur J Cancer Date: 2020-04-22 Impact factor: 9.162
Authors: Willem de Koning; Diba Latifi; Yunlei Li; Casper H J van Eijck; Andrew P Stubbs; Dana A M Mustafa Journal: Front Immunol Date: 2021-04-27 Impact factor: 7.561
Authors: E Borazanci; A M Schram; E Garralda; I Brana; M Vieito Villar; A Spreafico; M Oliva; N J Lakhani; K Hoffman; R M Hallett; D Maetzel; F Hua; J Hilbert; P Giblin; J Anido; A Kelly; P J Vickers; R Wasserman; J Seoane; L L Siu; D M Hyman; D V Hoff; J Tabernero Journal: ESMO Open Date: 2022-07-31